JessicaKaplanAltmanMD

Oncology • Chicago, IL

Hematologic Oncology

Professor in Medicine-Hematology/Oncology, Northwestern University Medical School

Join to view full profile

Dr. Altman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Altman's full profile

Already have an account?

Office
676 N Saint Clair St
Ste 850
Chicago, IL 60611
Phone+1 312-695-4125

Fax+1 312-695-7814

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
University of ChicagoResidency, Internal Medicine, 2001 - 2004
University of Pittsburgh School of MedicineClass of 2001

Certifications & Licensure

IL State Medical License 2004 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
Active, not recruiting
Phase 2
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Completed
Phase 2
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
Completed
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia Start of enrollment: 2011 Jun 01
Withdrawn
Phase 1
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Start of enrollment: 2011 Jul 01
Completed
Phase 2
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission Start of enrollment: 2012 Jul 01
Completed
Phase 1
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Start of enrollment: 2012 Sep 01
Completed
Phase 1
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Start of enrollment: 2012 Oct 01
Active, not recruiting
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients Start of enrollment: 2013 Apr 01
Completed
Phase 2
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Start of enrollment: 2015 Mar 11
Terminated
Phase 1
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2018 Nov 14
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2023 Jul 11
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Acute myeloid leukemia management and research in 2025.
Hagop M Kantarjian, Courtney D DiNardo, Tapan M Kadia, Naval G Daver, Jessica K Altman
CA. 2024-12-10
2 citations
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Eunice S Wang, Ghayas C Issa, Harry P Erba, Jessica K Altman, Pau Montesinos
The Lancet. Oncology. 2024-10-01
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia.
Andrew Palmer, Garth Rauscher, Ivy Abraham, Madelyn Burkart, Ami Dave
Blood Advances. 2024-09-10

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine

Lectures

Targeting Treatment According to Molecular Assessment of Acute Myeloid Leukemia
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
MDS + AML MATTER: A Multidisciplinary Approach to Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection
60th American Society of Hematology Annual Meeting - 12/1/2018
Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Highlights of ASH® San Diego, CA
American Society of Hematology (ASH), San Diego, California - 1/18/2013
Join now to see all

Press Mentions

Improving Treatment for Hairy Cell LeukemiaJanuary 11th, 2023
Study Shows Structural Racism Can Result in Poorer Leukemia OutcomesMarch 7th, 2022
Expect More Health Plans, Insurers, and Stable Premiums in 2022 as Part of Affordable Care ActAugust 10th, 2021
Join now to see all